Engineered proteins: A future treatment option for COVID-19

COVID-19 has had a lasting global health impact that continues to challenge the health care system. As the coronavirus continues to mutate, the current COVID-19 prevention strategies are plagued with supply chain disruptions, ...

The first potent COQ8 inhibitor targets ubiquinone biosynthesis

A new collaborative study from the University of Eastern Finland, Washington University in St. Louis, University of Wisconsin–Madison, University of North Carolina at Chapel Hill and the Promega Corporation discloses the ...

Can AI transform the way we discover new drugs?

The world's aging population, the growing burden of chronic and infectious diseases, and the emergence of novel pathogens have made the need for new treatments more urgent than ever. Yet, discovering a new drug and bringing ...

Preventing resistance in cancer therapy

The latest developmental drugs, particularly for use in oncology, rely on the targeted degradation of harmful pathogenic proteins. In a recent study published in Nature Chemical Biology, researchers at CeMM, the Research ...

New strategy to precisely target subtypes of key protein

Cyclosporine is one of the most common and effective immunosuppressant drugs used to treat chronic diseases like arthritis and psoriasis, but it comes with a risk of serious side effects. Scientists think that may be because ...

page 5 from 40